Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Belimumab

Nature Reviews Drug Discovery volume 10, pages 335–336 (2011)Cite this article

Subjects

Abstract

In March 2011, belimumab (Benlysta; Human Genome Sciences/GlaxoSmithKline), a human monoclonal antibody that is specific for the cytokine B lymphocyte stimulator, was approved by the US Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Smith, R. M. et al. Biological therapy for lupus nephritis — tribulations and trials. Nature Rev. Rheumatol. 6, 547–552 (2010).

    Google Scholar 

  2. Sanz, I. & Lee, F. E. B cells as therapeutic targets in SLE. Nature Rev. Rheumatol. 6, 326–337 (2010).

    CAS  Article  Google Scholar 

  3. Moore, P. A. et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260–263 (1999).

    CAS  Article  Google Scholar 

  4. Zhang, J. et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166, 6–10 (2001).

    CAS  Article  Google Scholar 

  5. Baker, K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253–3265 (2003).

    CAS  Article  Google Scholar 

  6. Halpern, W. G. et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. 91, 586–599 (2006).

    CAS  Article  Google Scholar 

  7. US Food and Drug Administration. FDA labelling information — Benlysta. FDA website [online], (2011).

  8. Wallace, D. J. et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).

    CAS  Article  PubMed Central  Google Scholar 

  9. Yee, M. et al. RBC Capital Markets Equity Research (28 Mar 2011).

    Google Scholar 

  10. Mehroti, R. et al. Human Genome Sciences (Credit Suisse Equity Research, 28 Mar 2011).

    Google Scholar 

Download references

Author information

Affiliations

  1. Iaki Sanz is at the Division of Allergy, Department of Medicine, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA.

    Iñaki Sanz

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.

    Peter Kirkpatrick

Authors
  1. Iñaki Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Iñaki Sanz, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

I.S. has consulted for GlaxoSmithKline (less than $5000) and has an ongoing research collaboration with Biogen Idec.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sanz, I., Yasothan, U. & Kirkpatrick, P. Belimumab. Nat Rev Drug Discov 10, 335–336 (2011). https://doi.org/10.1038/nrd3436

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3436

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing